ALYREF and neoplasm: Since the NSUN2/ALYREF/m5C‐PFAS oncogenic cascade is an important trigger of RB, our study provides a novel therapeutic strategy, namely, a ‘targeted m5C reprogramming strategy’, that may potentially be an efficient anti‐tumour therapy.